209 related articles for article (PubMed ID: 16935796)
21. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
Estève E; Bagot M; Joly P; Souteyrand P; Beylot-Barry M; Vaillant L; Delaunay M; Avril MF; Laroche L; Grange F; Thomine E; Wechsler J
Arch Dermatol; 1999 Nov; 135(11):1349-53. PubMed ID: 10566833
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
[TBL] [Abstract][Full Text] [Related]
23. [Photodynamic therapy of cutaneous T-cell lymphoma at special sites].
Eich D; Eich HT; Otte HG; Ghilescu V; Stadler R
Hautarzt; 1999 Feb; 50(2):109-14. PubMed ID: 10097953
[TBL] [Abstract][Full Text] [Related]
24. Treatment of mycosis fungoides with imiquimod 5% cream.
Ariffin N; Khorshid M
Clin Exp Dermatol; 2006 Nov; 31(6):822-3. PubMed ID: 17040269
[No Abstract] [Full Text] [Related]
25. Mycosis on mycosis fungoides: zoophilic dermatophytosis selectively superimposed on pre-existing cutaneous T-cell lymphoma (mycosis fungoides) plaques.
Capella GL; Altomare GF
Mycoses; 2003 Feb; 46(1-2):67-70. PubMed ID: 12588488
[TBL] [Abstract][Full Text] [Related]
26. Long-term remission of primary cutaneous neutrophil-rich CD30+ anaplastic large cell lymphoma treated with topical imiquimod. A case report.
Calista D; Riccioni L; Bagli L; Valenzano F
J Eur Acad Dermatol Venereol; 2016 May; 30(5):899-901. PubMed ID: 25809386
[No Abstract] [Full Text] [Related]
27. [Analytical study of 13 cases of cutaneous lymphoma].
Kort R; Mokni M; Rouatbi M; Azaiz MI; Kchir N; Haouet S; Boubaker S; Zitouna M; Ben Osman A
Tunis Med; 1995; 73(6-7):247-52. PubMed ID: 9506173
[No Abstract] [Full Text] [Related]
28. Primary cutaneous lymphomas: single center experience of dermatology and hematology clinics.
Payzin B; Ogretmen Z; Cidem Yildirim A; Ozturk Durur S; Sentekin S
J BUON; 2014; 19(1):171-7. PubMed ID: 24659660
[TBL] [Abstract][Full Text] [Related]
29. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
30. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
31. Complete Resolution of Primary Cutaneous Anaplastic Large Cell Lymphoma With Topical Imiquimod.
Kubicki SL; Park KE; Aung PP; Duvic M
J Drugs Dermatol; 2019 May; 18(5):460-462. PubMed ID: 31141854
[TBL] [Abstract][Full Text] [Related]
32. Imiquimod and the treatment of cutaneous T-cell proliferative diseases: at the threshold.
Herbert WC
Skinmed; 2003; 2(5):273-4. PubMed ID: 14673259
[No Abstract] [Full Text] [Related]
33. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
34. Pegylated liposomal doxorubicin in the treatment of cutaneous T-cell lymphoma.
Prince HM; Seymour JF; Ryan G; McCormack C
J Am Acad Dermatol; 2001 Jan; 44(1):149-50. PubMed ID: 11148501
[No Abstract] [Full Text] [Related]
35. [Mycosis fungoides following non-Hodgkin's cutaneous B-cell lymphoma].
Dereure O; Basset-Seguin N; Guilhou JJ
Ann Dermatol Venereol; 1993; 120(9):625-7. PubMed ID: 8161118
[TBL] [Abstract][Full Text] [Related]
36. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
38. [Topical imiquimod cream in the treatment of external anogenital warts: personal experience].
Senatori R; Dionisi B; Lippa P; Inghirami P
Minerva Ginecol; 2003 Dec; 55(6):541-6. PubMed ID: 14676745
[TBL] [Abstract][Full Text] [Related]
39. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study.
Dummer R; Krasovec M; Röger J; Sindermann H; Burg G
J Am Acad Dermatol; 1993 Dec; 29(6):963-70. PubMed ID: 8245262
[TBL] [Abstract][Full Text] [Related]
40. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
